Syk inhibitor

Hutchmed Sets Sights on Chinese Approval for Autoimmune Disorder Drug Following Phase 3 Triumph

Hutchmed, a prominent pharmaceutical player, is gearing up for a significant move as it readies to submit sovleplenib for regulatory ...